by Rishika Gupta on  February 22, 2018 at 12:01 PM Health Watch
  • Probenecid, a drug long used to treat gout, may now be able to improve heart function in adult patients who have experienced heart failure.
  • The drug is considered to be safe for all ages, it has also been found to improve two important characteristics of the heart failure.
  • Probenecid has shown an improvement in heart contraction, relaxation and ejection fraction of patients with heart failure.

 Probenecid Anti-gout Drug may Help Treat Heart Failure
Probenecid, a drug long used to treat gout, may also help improve heart function in patients who experience heart failure finds a new study. The findings of this study are published in the Journal of the American Heart Association.

"We were testing if probenecid was safe for patients," says Jack Rubinstein, MD, associate professor in the Division of Cardiovascular Health and Disease, and corresponding author for the study. "We know that it was very likely to be safe because the medicine had been taken by people of all ages for decades. It has a very strong safety profile. We were quite happily surprised it improved the two main ways in how the heart functions. It improves how the heart contracts and how it relaxes."

The patients were offered probenecid as part of a randomized, double-blind, crossover and placebo-controlled single-center clinical trial. Patients, who averaged 57 years of age, were enrolled during four-week periods between June 2013 and April 2015.

They were required to undergo an echocardiogram, an electrocardiogram and six-minute endurance test along with other assessments explains Rubinstein, a UC Health cardiologist and member of the UC Heart, Lung and Vascular Institute.

The study's first author is Nathan Robbins, a senior research assistant in the UC College of Medicine, who started out volunteering with Rubinstein in the laboratory examining the echocardiograms of animals treated with probenecid before later being hired to help recruit heart failure patients.

"This is the first time probenecid has been used in heart failure patients, and we showed it increases the ejection fraction in patients with heart failure," says Robbins. "It was exciting to be able to see this medicine work from the bench to the bedside."

Rubinstein also partnered with basic scientists led by Sakthivel Sadayappan, Ph.D., professor in the UC College of Medicine and director of the heart branch of the UC Heart, Lung and Vascular Institute. Sadayappan and his researchers examined probenecid in animal heart cells and found it improved how well the heart uses calcium, an important component of cardiac muscle contraction.

"The medicine works in ways we know about, and in ways, we don't know about," says Rubinstein. "For the past four or five years, we have been figuring out some of the ways the medicine works. We have figured out a lot of them, but there is still a lot we don't know."

Heart failure occurs when the heart pump is not strong enough to move blood throughout the body and meet the body's needs for oxygen, explains Rubinstein. It affects 5.7 million people in the United States, according to the Centers for Disease Control and Prevention.

"The repercussions are potentially significant--if we are able to confirm this experiment in larger studies with longer-term follow up--this could present a new way of treating heart failure for which there are limited medical therapies available," says Rubinstein.

"Left ventricular assist devices, pacemakers, heart transplants, and medications are available to treat heart failure patients, but outcomes for patients with heart failure are still worse than outcomes for the vast majority of cancer patients," says Rubinstein. "That's what we want to effectively change."

  1. Nathan Robbins, Mark Gilbert, Mohit Kumar, James W. McNamara, Patrick Daly, Sheryl E. Koch, Ginger Conway, Mohamed Effat, Jessica G. Woo, Sakthivel Sadayappan, Jack Rubinstein. Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro. Journal of the American Heart Association, 2018; 7 (2): e007148 DOI: 10.1161/JAHA.117.007148

Source: Eurekalert

Most Popular on Medindia